Response to Xiang and Zhang re: “Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status”
Restricted accessResearch articleFirst published online March, 2024
Response to Xiang and Zhang re: “Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status”
XiangJ, ZhangH. Re: “Active surveillance outcomes of patients with low-risk papillary thyroid microcarcinoma according to levothyroixine treatment status” by Yamamoto et al. Thyroid, 2024; 34(3)399–400; doi: 10.1089/thy.2023.0605
2.
YamamotoM, MiyauchiA, ItoY, et al.Active surveillance outcomes of patients with low-risk papillary thyroid microcarcinoma according to levothyroxine treatment status. Thyroid, 2023; 33(10):1182–1189; doi: 10.1089/thy.2023.0046
3.
KimHI, JangHW, AhnHS, et al.High serum TSH level is associated with progression of papillary thyroid microcarcinoma during active surveillance. J Clin Endocrinol Metab, 2018; 103(2):446–451; doi: 10.1210/jc.2017-01775
4.
ItoY, MiyauchiA, FujishimaM, et al.Thyroid-stimulating hormone, age, and tumor size are risk factors for progression during active surveillance of low-risk papillary thyroid microcarcinoma in adults. World J Surg, 2023; 47(2):392–401; doi: 10.1007/s00268-022-06770-z
5.
HaugenBR, AlexanderEK, BibleKC, et al.2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid, 2016; 26(1):1–133; doi: 10.1089/thy.2015.0020
6.
ItoM, MiyauchiA, MoritaS, et al.TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy. Eur J Endocrinol, 2012; 167(3):373–378; doi: 10.1530/EJE-11-1029
7.
ItoM, MiyauchiA, HisakadoM, et al.Biochemical markers reflecting thyroid function in athyreotic patients on levothyroxine monotherapy. Thyroid, 2017; 27(4):484–490; doi: 10.1089/thy.2016.0426
